
MHRA recall M&A Pharmachem’s paracetamol due to fungal contamination
pharmafile | June 18, 2019 | News story | Manufacturing and Production | Contamination, MHRA, fungal, paracetamol, pharma
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall of M&A Pharmachem’s 500mg paracetamol tablets.
The tablets, which were produced in two separate batches of one thousand each, were found to be contaminated with the fungi Penicillium citrinium and Penicillium brevicompactum.
A number of tablets in each batch were found to be discoloured due to the fungal contamination.
However officials believe that patients have not taken the drugs as the discolouration is noticeable on opening the pack.
Wholesalers and healthcare professionals have been advised to stop supplying the affected batches as a quarantine has been put in place so that any remaining stock can be sent back to the supplier.
Louis Goss
Related Content

MHRA awards Innovation Passports to liver cancer and dementia medicines
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that two investigational medicines targeting …

MHRA approves first lower-carbon beclometasone inhalers for asthma
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first pressurised metered …

MHRA to establish Northern Ireland hub for life sciences sector
The Medicines and Healthcare products Regulatory Agency (MHRA) is establishing a new hub in Northern …






